Impact of early CMV reactivation in cord blood stem cell recipients in the current era

M. Ramanathan; P. Teira; M. Battiwalla; J. Barrett; K. W. Ahn; M. Chen; J. Green; M. Laughlin; H. M. Lazarus; D. Marks; A. Saad; M. Seftel; W. Saber; B. Savani; E. K. Waller; J. Wingard; J. J. Auletta; C. A. Lindemans; M. Boeckh; M. L. Riches

doi:10.1038/bmt.2016.89

Impact of early CMV reactivation in cord blood stem cell recipients in the current era

M. Ramanathan, P. Teira, M. Battiwalla, J. Barrett, K. W. Ahn, M. Chen, J. Green, M. Laughlin, H. M. Lazarus, D. Marks, A. Saad, M. Seftel, W. Saber, B. Savani, E. K. Waller, J. Wingard, J. J. Auletta, C. A. Lindemans, M. Boeckh, M. L. Riches

Medicine - Infectious Disease and International Medicine

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Several studies have reported an association between CMV reactivation and a decreased incidence of relapse for AML after adult donor allogeneic hematopoietic cell transplantation (HCT). Limited data, however, are available on the impact of CMV reactivation on relapse after cord blood (CB) stem cell transplantation. The unique combination of higher incidence of CMV reactivation in the seropositive recipient and lower incidence of graft versus host disease (GvHD) in CB HCT permits a valuable design to analyze the impact of CMV reactivation. Data from 1684 patients transplanted with CB between 2003 and 2010 for AML and ALL were analyzed. The median time to CMV reactivation was 34 days (range: 2-287). CMV reactivation and positive CMV serology were associated with increased non-relapse mortality (NRM) among both AML and ALL CB recipients (reactivation, AML: relative risk (RR) 1.41 (1.07-1.85); ALL: 1.60 (1.14-2.23); Serology, AML: RR 1.39 (1.05-1.85), ALL: RR 1.61 (1.18-2.19)). For patients with ALL, but not those with AML, this yielded inferior overall survival (P<0.005). Risk of relapse was not influenced by CMV reactivation or positive CMV serostatus for either disease.

Original language	English (US)
Pages (from-to)	1113-1120
Number of pages	8
Journal	Bone marrow transplantation
Volume	51
Issue number	8
DOIs	https://doi.org/10.1038/bmt.2016.89
State	Published - Aug 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Macmillan Publishers Limited, part of Springer Nature.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/bmt.2016.89

http://europepmc.org/articles/pmc4972682

Find It

Find It at U of M Libraries

Cite this

Ramanathan, M., Teira, P., Battiwalla, M., Barrett, J., Ahn, K. W., Chen, M., Green, J., Laughlin, M., Lazarus, H. M., Marks, D., Saad, A., Seftel, M., Saber, W., Savani, B., Waller, E. K., Wingard, J., Auletta, J. J., Lindemans, C. A., Boeckh, M., & Riches, M. L. (2016). Impact of early CMV reactivation in cord blood stem cell recipients in the current era. Bone marrow transplantation, 51(8), 1113-1120. https://doi.org/10.1038/bmt.2016.89

Ramanathan, M, Teira, P, Battiwalla, M, Barrett, J, Ahn, KW, Chen, M, Green, J, Laughlin, M, Lazarus, HM, Marks, D, Saad, A, Seftel, M, Saber, W, Savani, B, Waller, EK, Wingard, J, Auletta, JJ, Lindemans, CA, Boeckh, M & Riches, ML 2016, 'Impact of early CMV reactivation in cord blood stem cell recipients in the current era', Bone marrow transplantation, vol. 51, no. 8, pp. 1113-1120. https://doi.org/10.1038/bmt.2016.89

@article{5806d7660bee47d28ef3cb8d3af103e8,

title = "Impact of early CMV reactivation in cord blood stem cell recipients in the current era",

abstract = "Several studies have reported an association between CMV reactivation and a decreased incidence of relapse for AML after adult donor allogeneic hematopoietic cell transplantation (HCT). Limited data, however, are available on the impact of CMV reactivation on relapse after cord blood (CB) stem cell transplantation. The unique combination of higher incidence of CMV reactivation in the seropositive recipient and lower incidence of graft versus host disease (GvHD) in CB HCT permits a valuable design to analyze the impact of CMV reactivation. Data from 1684 patients transplanted with CB between 2003 and 2010 for AML and ALL were analyzed. The median time to CMV reactivation was 34 days (range: 2-287). CMV reactivation and positive CMV serology were associated with increased non-relapse mortality (NRM) among both AML and ALL CB recipients (reactivation, AML: relative risk (RR) 1.41 (1.07-1.85); ALL: 1.60 (1.14-2.23); Serology, AML: RR 1.39 (1.05-1.85), ALL: RR 1.61 (1.18-2.19)). For patients with ALL, but not those with AML, this yielded inferior overall survival (P<0.005). Risk of relapse was not influenced by CMV reactivation or positive CMV serostatus for either disease.",

author = "M. Ramanathan and P. Teira and M. Battiwalla and J. Barrett and Ahn, {K. W.} and M. Chen and J. Green and M. Laughlin and Lazarus, {H. M.} and D. Marks and A. Saad and M. Seftel and W. Saber and B. Savani and Waller, {E. K.} and J. Wingard and Auletta, {J. J.} and Lindemans, {C. A.} and M. Boeckh and Riches, {M. L.}",

note = "Publisher Copyright: {\textcopyright} 2016 Macmillan Publishers Limited, part of Springer Nature.",

year = "2016",

month = aug,

day = "1",

doi = "10.1038/bmt.2016.89",

language = "English (US)",

volume = "51",

pages = "1113--1120",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Impact of early CMV reactivation in cord blood stem cell recipients in the current era

AU - Ramanathan, M.

AU - Teira, P.

AU - Battiwalla, M.

AU - Barrett, J.

AU - Ahn, K. W.

AU - Chen, M.

AU - Green, J.

AU - Laughlin, M.

AU - Lazarus, H. M.

AU - Marks, D.

AU - Saad, A.

AU - Seftel, M.

AU - Saber, W.

AU - Savani, B.

AU - Waller, E. K.

AU - Wingard, J.

AU - Auletta, J. J.

AU - Lindemans, C. A.

AU - Boeckh, M.

AU - Riches, M. L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Several studies have reported an association between CMV reactivation and a decreased incidence of relapse for AML after adult donor allogeneic hematopoietic cell transplantation (HCT). Limited data, however, are available on the impact of CMV reactivation on relapse after cord blood (CB) stem cell transplantation. The unique combination of higher incidence of CMV reactivation in the seropositive recipient and lower incidence of graft versus host disease (GvHD) in CB HCT permits a valuable design to analyze the impact of CMV reactivation. Data from 1684 patients transplanted with CB between 2003 and 2010 for AML and ALL were analyzed. The median time to CMV reactivation was 34 days (range: 2-287). CMV reactivation and positive CMV serology were associated with increased non-relapse mortality (NRM) among both AML and ALL CB recipients (reactivation, AML: relative risk (RR) 1.41 (1.07-1.85); ALL: 1.60 (1.14-2.23); Serology, AML: RR 1.39 (1.05-1.85), ALL: RR 1.61 (1.18-2.19)). For patients with ALL, but not those with AML, this yielded inferior overall survival (P<0.005). Risk of relapse was not influenced by CMV reactivation or positive CMV serostatus for either disease.

AB - Several studies have reported an association between CMV reactivation and a decreased incidence of relapse for AML after adult donor allogeneic hematopoietic cell transplantation (HCT). Limited data, however, are available on the impact of CMV reactivation on relapse after cord blood (CB) stem cell transplantation. The unique combination of higher incidence of CMV reactivation in the seropositive recipient and lower incidence of graft versus host disease (GvHD) in CB HCT permits a valuable design to analyze the impact of CMV reactivation. Data from 1684 patients transplanted with CB between 2003 and 2010 for AML and ALL were analyzed. The median time to CMV reactivation was 34 days (range: 2-287). CMV reactivation and positive CMV serology were associated with increased non-relapse mortality (NRM) among both AML and ALL CB recipients (reactivation, AML: relative risk (RR) 1.41 (1.07-1.85); ALL: 1.60 (1.14-2.23); Serology, AML: RR 1.39 (1.05-1.85), ALL: RR 1.61 (1.18-2.19)). For patients with ALL, but not those with AML, this yielded inferior overall survival (P<0.005). Risk of relapse was not influenced by CMV reactivation or positive CMV serostatus for either disease.

UR - http://www.scopus.com/inward/record.url?scp=84962090317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962090317&partnerID=8YFLogxK

U2 - 10.1038/bmt.2016.89

DO - 10.1038/bmt.2016.89

M3 - Article

C2 - 27042847

AN - SCOPUS:84962090317

SN - 0268-3369

VL - 51

SP - 1113

EP - 1120

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 8

ER -

Impact of early CMV reactivation in cord blood stem cell recipients in the current era

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this